Cargando…

Radiation therapy outcomes of patients with pituitary macroadenoma

Pituitary adenomas are one of the most common benign intracranial tumors, which are normally treated with surgery along with radiation therapy and medication such as dopamine agonist in prolactinoma. The aim of the present study was to evaluate the outcome of patients with pituitary macroadenoma who...

Descripción completa

Detalles Bibliográficos
Autores principales: Khan, Sardar Ali, Shafiq, Waqas, Azmat, Umal, Siddiqi, Ahmed Imran, Alvi, Asim Munir, Ashfaq, Sara, Irfan, Hira, Bakar, Muhammad Abu, Asghar, Kashif
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9764322/
https://www.ncbi.nlm.nih.gov/pubmed/36568037
http://dx.doi.org/10.3892/br.2022.1594
_version_ 1784853250898395136
author Khan, Sardar Ali
Shafiq, Waqas
Azmat, Umal
Siddiqi, Ahmed Imran
Alvi, Asim Munir
Ashfaq, Sara
Irfan, Hira
Bakar, Muhammad Abu
Asghar, Kashif
author_facet Khan, Sardar Ali
Shafiq, Waqas
Azmat, Umal
Siddiqi, Ahmed Imran
Alvi, Asim Munir
Ashfaq, Sara
Irfan, Hira
Bakar, Muhammad Abu
Asghar, Kashif
author_sort Khan, Sardar Ali
collection PubMed
description Pituitary adenomas are one of the most common benign intracranial tumors, which are normally treated with surgery along with radiation therapy and medication such as dopamine agonist in prolactinoma. The aim of the present study was to evaluate the outcome of patients with pituitary macroadenoma who underwent radiation therapy. For the present retrospective study, a total of 75 patients with pituitary macroadenoma who received radiation therapy were included. Data was acquired from the electronic medical record system of the hospital. Mean ± standard deviation of the quantitative variables, such as age and sizes of the tumors, were reported. In addition, frequencies and percentages were presented for all categorical variables. To compare the frequency distribution in radiation therapy characteristics between functional and non-functional tumors, the χ(2) test or Fisher's exact test was applied, where appropriate. Kaplan-Meier survival curve was drawn to assess the progression free survival proportion. P≤0.05 was considered to indicate a statistically significant difference. In the present study, all patients (n=75) with pituitary macroadenoma were treated with radiation therapy (RT). The mean age was 38.55±1.36 years and the majority of the patients were male (43; 57.3%). The mean tumor size was 3.84±1.43 cm. In total, 66.7% were non-functional tumors whereas 33.3% were functional tumors that produce hormones in excess [growth hormone (72%), prolactin (16%), both growth hormone and prolactin (8%) and adrenocorticotropic hormone (4%)]. The overall outcome was revealed to be 92% achieving local tumor control and 28% achieving biochemical control. Hypopituitarism (38.7%) and visual acuity deterioration (9.3%) were the most common complications observed following RT. The overall progression-free survival at 2 years was 92%. In conclusion, the data of the present study suggested that local tumor control in non-functional and functional pituitary macroadenoma can be well managed with RT. However, biochemical control to normalize hormones overproduction in functional pituitary macroadenoma was not as effective as local tumor control.
format Online
Article
Text
id pubmed-9764322
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-97643222022-12-22 Radiation therapy outcomes of patients with pituitary macroadenoma Khan, Sardar Ali Shafiq, Waqas Azmat, Umal Siddiqi, Ahmed Imran Alvi, Asim Munir Ashfaq, Sara Irfan, Hira Bakar, Muhammad Abu Asghar, Kashif Biomed Rep Articles Pituitary adenomas are one of the most common benign intracranial tumors, which are normally treated with surgery along with radiation therapy and medication such as dopamine agonist in prolactinoma. The aim of the present study was to evaluate the outcome of patients with pituitary macroadenoma who underwent radiation therapy. For the present retrospective study, a total of 75 patients with pituitary macroadenoma who received radiation therapy were included. Data was acquired from the electronic medical record system of the hospital. Mean ± standard deviation of the quantitative variables, such as age and sizes of the tumors, were reported. In addition, frequencies and percentages were presented for all categorical variables. To compare the frequency distribution in radiation therapy characteristics between functional and non-functional tumors, the χ(2) test or Fisher's exact test was applied, where appropriate. Kaplan-Meier survival curve was drawn to assess the progression free survival proportion. P≤0.05 was considered to indicate a statistically significant difference. In the present study, all patients (n=75) with pituitary macroadenoma were treated with radiation therapy (RT). The mean age was 38.55±1.36 years and the majority of the patients were male (43; 57.3%). The mean tumor size was 3.84±1.43 cm. In total, 66.7% were non-functional tumors whereas 33.3% were functional tumors that produce hormones in excess [growth hormone (72%), prolactin (16%), both growth hormone and prolactin (8%) and adrenocorticotropic hormone (4%)]. The overall outcome was revealed to be 92% achieving local tumor control and 28% achieving biochemical control. Hypopituitarism (38.7%) and visual acuity deterioration (9.3%) were the most common complications observed following RT. The overall progression-free survival at 2 years was 92%. In conclusion, the data of the present study suggested that local tumor control in non-functional and functional pituitary macroadenoma can be well managed with RT. However, biochemical control to normalize hormones overproduction in functional pituitary macroadenoma was not as effective as local tumor control. D.A. Spandidos 2022-12-08 /pmc/articles/PMC9764322/ /pubmed/36568037 http://dx.doi.org/10.3892/br.2022.1594 Text en Copyright: © Khan et al. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
spellingShingle Articles
Khan, Sardar Ali
Shafiq, Waqas
Azmat, Umal
Siddiqi, Ahmed Imran
Alvi, Asim Munir
Ashfaq, Sara
Irfan, Hira
Bakar, Muhammad Abu
Asghar, Kashif
Radiation therapy outcomes of patients with pituitary macroadenoma
title Radiation therapy outcomes of patients with pituitary macroadenoma
title_full Radiation therapy outcomes of patients with pituitary macroadenoma
title_fullStr Radiation therapy outcomes of patients with pituitary macroadenoma
title_full_unstemmed Radiation therapy outcomes of patients with pituitary macroadenoma
title_short Radiation therapy outcomes of patients with pituitary macroadenoma
title_sort radiation therapy outcomes of patients with pituitary macroadenoma
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9764322/
https://www.ncbi.nlm.nih.gov/pubmed/36568037
http://dx.doi.org/10.3892/br.2022.1594
work_keys_str_mv AT khansardarali radiationtherapyoutcomesofpatientswithpituitarymacroadenoma
AT shafiqwaqas radiationtherapyoutcomesofpatientswithpituitarymacroadenoma
AT azmatumal radiationtherapyoutcomesofpatientswithpituitarymacroadenoma
AT siddiqiahmedimran radiationtherapyoutcomesofpatientswithpituitarymacroadenoma
AT alviasimmunir radiationtherapyoutcomesofpatientswithpituitarymacroadenoma
AT ashfaqsara radiationtherapyoutcomesofpatientswithpituitarymacroadenoma
AT irfanhira radiationtherapyoutcomesofpatientswithpituitarymacroadenoma
AT bakarmuhammadabu radiationtherapyoutcomesofpatientswithpituitarymacroadenoma
AT asgharkashif radiationtherapyoutcomesofpatientswithpituitarymacroadenoma